Floatz logo

Plixorafenib

Histiocytosis

Fore BiotherapeuticsSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Histiocytosis cohort.

Asset / SponsorPhaseRating
s241656
Institut de Recherches Internationales Servier
Phase 1/2CCC
Cetuximab
Institut de Recherches Internationales Servier
Phase 1/2CCC
PANITUMUMAB
Institut de Recherches Internationales Servier
Phase 1/2CCC

Same molecule, other indications

Plixorafenib is also rated in:

neoplasmDormant
B
Indicative ·
56 / 100
View asset →
Cancer Harboring BRAF AlterationsDormant
CCC
Indicative ·
50 / 100
View asset →
malignant gliomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →